¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"sexual response cycle"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • nitrogen cycle
    Áú¼Ò¼øÈ¯, Áú¼Ò»çÀÌŬ
  • oogenetic cycle
    ³­¼ÒÁÖ±â
  • ovarian cycle
    ³­¼ÒÁÖ±â
  • ovulation cycle
    ¹è¶õÁÖ±â
  • photochemical cycle
    ±¤È­ÇÐȸ·Î
  • pulse cycle
    ¸Æ¹ÚÁÖ±â
  • pain-spasm-pain cycle
    ÅëÁõ¿¬ÃàÅëÁõÁÖ±â
  • reproduction cycle
    »ý½ÄÁÖ±â
  • reversible cycle
    °¡¿ªÈ¸·Î
  • sporogenous cycle
    Ȧ¾¾Çü¼º±â, Æ÷ÀÚÇü¼º±â
  • sylvatic life cycle
    ¾ß»ý»ýȰÁÖ±â
  • urea cycle
    ¿ä¼Òȸ·Î
  • egosyntonic sexual orientation
    ÀھƵ¿Á¶Àû¼ºÁö³²·Â
  • female sexual arousal disorder
    ¿©¼º¼º(Àû)ÈïºÐÀå¾Ö
  • hypoactive sexual desire disorder
    ¼º¿å°¨¼Òº´
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • oogenetic cycle
    (¢¡ovarian cycle) ³­¼ÒÁÖ±â
  • ovarian cycle
    ³­¼ÒÁÖ±â
  • ovulation cycle
    ¹è¶õÁÖ±â
  • photochemical cycle
    ±¤È­ÇÐȸ·Î
  • pulse cycle
    ¸Æ¹ÚÁÖ±â
  • reproduction cycle
    »ý½ÄÁÖ±â
  • reversible cycle
    °¡¿ªÈ¸·Î
  • sporogenous cycle
    Ȧ¾¾Çü¼º±â, Æ÷ÀÚÇü¼º±â
  • sylvatic life cycle
    ¾ß»ý»ýȰÁÖ±â
  • tricarboxylic acid cycle
    »ïÄ«¸£º¹½Ç»êȸ·Î
  • sexual abstinence
    ±Ý¿å
  • sexual abuse
    ¼ºÆøÇà, ¼ºÇдë
  • sexual activity
    ¼ºÈ°µ¿
  • sexual ambiguity
    ¼ºº°¸ðÈ£
  • sexual assault
    ¼ºÆøÇà
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • antibody response
    Ç×ü¹ÝÀÀ(¡­Úãëë).
  • approximate response
    ±Ù»ç¹ÝÀÀ
  • arousal reaction=arousal response
    °¢¼º¹ÝÀÀ(ÊÆá¥Úãëë)
  • frenquency response curve
    Á֯ļö ¹ÝÀÀ°î¼±
  • galvanic skin response =GSR
    Àü±âÇǺιÝÀÀ(ï³Ñ¨ù«Ý±Úãëë).
  • galvanic skin response audiometry
    ÇǺÎÀü±â¹ÝÀÀ û·Â°Ë»ç
  • heat shock response
    ¿­Ãæ°Ý¹ÝÀÀ
  • ideosyncratic drug response
    ƯÀ̼º ¾à¹° ¹ÝÀÀ
  • immune response
    ¸é¿ªÀÀ´ä.
  • immune response
    ¸é¿ª¹ÝÀÀ
  • immune response
    ¸é¿ªÀÀ´ä.
  • immune response
    ¸é¿ªÀÀ´ä.
  • immune response gene
    ¸é¿ª¹ÝÀÀÀ¯ÀüÀÚ.
  • immune response gene
    ¸é¿ª¹ÝÀÀÀ¯ÀüÀÚ
  • immune response suppression
    ¸é¿ª¹ÝÀÀ¾ïÁ¦<--¾ï¾Ð>
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • sexual deviation, fetishism
    ÀýÆí(À½¶õÁõ) ¼º¿å.
  • sexual deviation, homosexuality
    µ¿¼º¾Ö.
  • sexual deviation, pedophilia
    ±â¾ÆÁõ.
  • sexual deviation, transvestism
    À̼ººÐÀåÁõ.
  • sexual deviation, voyeurism
    Àý½ÃÁõ.
  • sexual differentiation
  • sexual dimorphism
    ¼ºÀûÀ̼º
  • sexual dimorphism
    ¼ºÀû ÀÌÇü¼º
  • sexual disinhibition
    ¼ºÀû Å»¾ïÁ¦
  • sexual disorder
    ¼ºÀå¾Ö
  • sexual drive
    ¼ºÀû ¿åµ¿
  • sexual dysfunction
    ¼º±â´ÉÀå¾Ö
  • sexual dysfunction
    ¼º±â´É°ï¶õ
  • sexual exploitation
    ¼ºÀû ÂøÃë
  • sexual fantasy
    ¼ºÀû ȯ»ó
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • carbon-fixation cycle
    ź¼Ò°íÁ¤ ȸ·Î(÷©áÈͳïÒüÞÖØ)
  • carbon-oxygen cycle
    ź¼Ò»ê¼Ò ȸ·Î(÷©áÈß«áÈüÞÖØ)
  • carbon reduction cycle
    ź¼Ò ȯ¿ø ȸ·Î(÷©áÈü½êªüÞÖØ)
  • cell cycle
    ¼¼Æ÷ÁÖ±â(á¬øàñÎÑ¢)
  • citrate cycle
    ½ÃÆ®¸£»êȸ·Î(ß«üÞÖØ)
  • citrate-pyruvate cycle
    ½ÃÆ®¸£»ê(ß«)-ÇǸ£ºê»êȸ·Î(ß«üÞÖØ)
  • citric acid cycle
    ½ÃÆ®¸£»êȸ·Î(ß«üÞÖØ)
  • Cori cycle
    ÄÚ¸® ȸ·Î(üÞÖØ)
  • cycle
    "°í¸®, ȸ·Î(üÞÖØ), ȯ»ó(ü»ßÒ)"
  • dicarboxylic acid cycle
    "ÀÌ(ì£)Ä«¸£º¹½Ç»ê(ß«) ȸ·Î(üÞÖØ), (ÔÒ) glyoxylate cycle"
  • elongation cycle
    ¿¬ÀåÁÖ±â (æÅíþñÎÑ¢)
  • futile cycle
    ¹«ÀÍ È¸·Î(ÙíìÌüÞÖØ)
  • generation cycle
    ¼¼´ë ÁÖ±â(á¦ÓÛñÎÑ¢)
  • glucose-alanine cycle
    ±Û·çÄÚ½º-¾Ë¶ó´Ñ ȸ·Î(üÞÖØ)
  • ¥ã-glutamyl cycle
    ¥ã-±Û·çŸ¹Ð ȸ·Î(üÞÖØ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
IR drop of voltage across a resistor produced by a current; ileal resection; immune response; immunizat...
MLR mean length response; middle latency response; mixed lymphocyte reaction
PR by way of the rectum [Lat. per rectum]; far point [of accommodation] [Lat. punctum remotum]; palindr...
RVR reduced vascular response; renal vascular resistance; repetitive ventricular response; resistance to...
SER sebum excretion rate; sensitizer enhancement ratio; sensory evoked response; service; smooth endopla...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
CL Cycle Length
SCL Sinus Cycle Length
SSC Stretch-shortening cycle
CDC2 cell division cycle 2
C cycle
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • menstural cycle
    ¿ù°æ ÁÖ±â
    ¿ù°æ ÁÖ±â´Â ¿ù°æ ÃâÇ÷ °³½Ã ù³¯ºÎÅÍ ´ÙÀ½ ¿ù°æ ÃâÇ÷ °³½Ã Àü³¯±îÁöÀÇ Àϼö¸¦ ¸»Çϸç, ¿ù°æ ÃâÇ÷ÀÌ ³¡³­ ÈÄ¿¡ ¼¼´Â °ÍÀº ¾Æ´Ï´Ù. Á¤»ó ÁÖ±â´Â 25~38ÀÏÀ̶ó°í »ý°¢ÇÏ¸é µÇ°í, ±âÃÊ Ã¼¿ÂÀÇ Àú¿Â»ó¿¡ ÇØ´çÇÏ´Â ¿©Æ÷±â
  • metabdic cycle
    ´ë»ç ÁÖ±â
  • mitotic cycle
    À¯»ç ºÐ¿­ ȯ
  • muscle pain cycle
    ±ÙÅëÁõ ÁÖ±â, ±Ùµ¿Åë ÁÖ±â
  • nitrogen cycle
    Áú¼Ò ¼øÈ¯
  • ovulation cycle
    ¹è¶õ ÁÖ±â
  • pulse cycle
    ¸Æ¹Ú ÁÖ±â
  • self-generating pain cycle
    µ¿ÅëÀ» À¯¹ßÇÏ´Â ÀÚ¹ßÀûÀÎ ¼øÈ¯ °úÁ¤
  • sulfur cycle
    Ȳ ¼øÈ¯
  • adaptive response
    ÀûÀÀ ¹ÝÀÀ
    µ¿ÀǾî=ada
  • age-response function
    ¿¬·É ¹ÝÀÀ ÇÔ¼ö
  • alerting response
    °¢¼º ¹ÝÀÀ
  • amnestic response
    °Ç¸Á ¹ÝÀÀ
  • antibody response
    Ç×ü ¹ÝÀÀ
  • approximate response
    ±Ù»ç ¹ÝÀÀ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
galvanic skin response A change in electrical resistance of the skin, occurring in emotion and in certain other conditions.
(12 Dec 1998)
recruiting response <neurology> The gradual increase to a maximum in a reflex when a stimulus of unaltered intensity is prolonged.
(12 Dec 1998)
partial response <oncology> A decrease of at least 50 percent in the sum of the measurements of all evaluable target lesions or tumours seen in a study.
(16 Dec 1997)
relaxation response An integrated hypothalamic reaction resulting in decreased sympathetic nervous system activity which, physiologically and psychologically, is almost a mirror image of the body's response's to Cannon's emergency theory (flight or fight response); can be self-induced through the use of techniques associated with transcendental meditation, yoga, and biofeedback.
See: emergency theory.
(05 Mar 2000)
response An action or movement due to the application of a stimulus.
Origin: L. Respondere = to answer, reply
(18 Nov 1997)
response generalisation <biology> The principle that after an organism learns to respond in a particular manner to a stimulus, that stimulus is effective in eliciting similar responses.
(12 Dec 1998)
response hierarchy Alternative reactions or modes of adjustment to a given situation arranged in the probable order of prior effectiveness; e.g., a mother attempting to discipline an unruly child may first request, cajole, then plead, scold, and finally punish; her behaviours can be ordered along a response hierarchy for further monitoring of effectiveness.
(05 Mar 2000)
response rate <oncology> The percentage of patients showing partial or complete response to the given treatment.
(16 Dec 1997)
graft-versus-host response <haematology> A common and serious, complication of bone marrow transplantation where there is a reaction of donated bone marrow against a patient's own tissue.
When donor lymphocytes or a graft containing lymphocytes that are immunologically competent are given to a patient that has low immunological competence, an incompatibility reaction can result. This is due to antibodies from the donor against antigens in the host. This is due to mismatch of MHC Class I antigens and can produce lymphocyte clones that will react by a variety of processes against the host and cause damage.
The clinical condition can be fatal and is due to the donor's immune cells recognising the host cells as foreign.
The clinical entity characterised by anorexia, diarrhoea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the graft-versus-host reaction. It can occur in either chronic or acute forms and is treatable by immunosuppressive drugs.
Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin.
Radiological appearances of the gastrointestinal tract include; thickened wall, mucosal folds thickened or effaced, increased secretions most likely to be rapid transit of GI tract, mass most likely to be focal oedema, fibrosis, hallmark: diffuse, uniform thickening of small bowel.
Synonym: GVH disease.
Acronym: GVHD
(20 Sep 2002)
complete response <oncology> The disappearance of all clinical evidence of disease. Unfortunately, this does not necessarily mean cure, as microscopic metastases may remain undetected, are likely to regrow and become resistant to treatment.
May also be used in relation to a pathological specimen, where no residual abnormality can be detected in the specimen, in which cas it is referred to as a pathological complete reponse.
Acronym: CR
(16 Mar 1998)
concentration-response curve <pharmacology> This is a graph produced to show the relation between the exposure concentration of a drug (or other chemical) and the degree of response it produces, as measured by the percentage of the exposed population showing a defined, often quantal, effect.
(05 Jan 1998)
conditioned response A response already in an individual's repertoire but which, through repeated pairings with its natural stimulus, has been acquired or conditioned anew to a previously neutral or conditioned stimulus.
See: conditioning.
Compare: unconditioned response.
(05 Mar 2000)
Cushing response A rise in systemic blood pressure when the intracranial pressure acutely increases, usually in excess of 50% of the systolic arterial pressure.
Synonym: Cushing effect, Cushing response.
(05 Mar 2000)
primary antibody response <immunology> Antibodies made upon first exposure to an antigen, mostly of the class IgM.
(05 Mar 1998)
primary immune response <immunology> The immune response to the first challenge by a particular antigen. Usually less extensive than the secondary immune response, being slower and shorter lived with smaller amounts of lower affinity antibody being produced.
(18 Nov 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • product life cycle
    Á¦Ç°ÀÇ ¶óÀÌÇÁ »çÀÌŬ
  • solar cycle
    ÅÂ¾ç ¼øÈ¯±â;28 ÁÖ³â
  • trade cycle
    °æ±â ¼øÈ¯
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á